A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma

Trial Profile

A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Ceritinib (Primary)
  • Indications Anaplastic large cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Apr 2018 Planned End Date changed from 1 Apr 2023 to 1 Jul 2023.
    • 20 Apr 2018 Planned primary completion date changed from 1 Apr 2023 to 1 Jul 2023.
    • 12 Jan 2018 Planned End Date changed from 1 Feb 2023 to 1 Apr 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top